Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
AI is driving down the price of knowledge – universities have to rethink what they offer 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want 
A sugar replacement called erythritol found in Splenda and Equal has been linked by a study to blood clotting, stroke, heart attack, and death.
Erythritolused is used to add bulk or sweeten stevia, monkfruit and keto reduced-sugar products.
Lead study author Dr. Stanley Hazen, director of the Center for Cardiovascular Diagnostics and Prevention at the Cleveland Clinic Lerner Research Institute, warned that “the degree of risk was not modest.”
The study, released on Monday in the journal Nature Medicine, found that people with pre-existing risk factors for heart disease, such as diabetes, were twice as likely to have a heart attack or stroke if they had the highest amounts of erythritol in their blood.
According to Hazen, there was an approximately two-fold increased risk for heart attack and stroke for those whose blood level of erythritol was in the top 25 percent as opposed to the lowest 25 percent. It is comparable to the most serious cardiac risk factors, such as diabetes.
Additional lab and animal research presented in the paper revealed that erythritol appeared to be causing blood platelets to clot more readily. Clots can break off and travel to the heart, triggering a heart attack, or to the brain, triggering a stroke.
Dr. Andrew Freeman, director of cardiovascular prevention and wellness at National Jewish Health, a hospital in Denver, said there appears to be a clotting risk from using erythritol, and that it might make sense to limit erythritol in your diet for now.”
Freeman was not involved in the research.
In response to the study, Robert Rankin, executive director of the Calorie Control Council, an industry association, said that “the results of this study are contrary to decades of scientific research showing reduced-calorie sweeteners like erythritol are safe, as evidenced by global regulatory permissions for their use in foods and beverages.”
Rankin added that the results “should not be extrapolated to the general population, as the participants in the intervention were already at increased risk for cardiovascular events.”
